Idiopathic pulmonary fibrosis (IPF) pathogenesis may soon have new therapeutic targets, according to multiomics research published in Respir Res in 2026 by Yue M et al. The progressive and irreversible interstitial lung disease, which carries a high mortality rate, has been linked to lactylation—a recently identified posttranslational modification. While researchers previously understood that lactylation contributes to inflammation and tissue fibrosis, its exact mechanical contribution to IPF remained incompletely understood until a recent multiomics analysis identified three lactylation-related hub genes.
Identifying DDX3X, BCLAF1, and NCL as IPF Hub Genes
The research team analyzed transcriptomic and single-cell sequencing data from lung tissue collected from patients with IPF and healthy controls, according to the study by Yue M et al. Investigators used gene coexpression analysis, protein interaction networks, and cellular clustering to isolate genes associated with both lactylation and IPF. This rigorous screening pointed to DDX3X, BCLAF1, and NCL as central lactylation-related genes governing disease progression through epithelial changes, fibroblast activation, and remodeling of the immune environment.
Did you know?
Expression levels of these three genes varied distinctly across lung cell populations. DDX3X appeared primarily in macrophages and neutrophils, BCLAF1 localized in ciliated epithelial cells, and NCL was detected in lung fibroblasts and macrophages, as outlined by Yue M et al. Furthermore, all three genes showed significant upregulation in IPF tissue compared with healthy lung tissue, while overall lactylation levels were markedly elevated in IPF lungs and cellular models stimulated with transforming growth factor beta 1.
Gene Knockdown and Suppression of Fibrotic Activity
Functional experiments in the study provided preliminary evidence that DDX3X, BCLAF1, and NCL actively drive fibrotic mechanisms, according to Yue M et al. When researchers individually suppressed these three genes, the intervention significantly inhibited alveolar epithelial-to-mesenchymal transition and reduced the activation of human fetal lung fibroblasts.
These biological processes sit at the heart of fibrotic remodeling. Epithelial-to-mesenchymal transition generates cells with aggressive profibrotic properties, whereas activated fibroblasts fuel excessive extracellular matrix accumulation and progressive lung scarring. Additionally, the study noted that these hub genes associate closely with altered immune cell infiltration, indicating that aberrant lactylation supports a profibrotic immune microenvironment in idiopathic pulmonary fibrosis patients.
Pro Tip: When evaluating early-stage multiomics research in pulmonology, always check whether computational predictions have been paired with in vitro or in vivo functional validation assays to confirm actual disease relevance.
Molecular Docking and Future Antifibrotic Treatment Horizons
Molecular docking analyses conducted by the research team revealed favorable predicted binding between the proteins encoded by DDX3X, BCLAF1, and NCL and existing therapeutic compounds like pirfenidone and curcumin, according to Yue M et al. However, the authors caution that these computational findings do not establish clinical effectiveness on their own and require rigorous further experimental validation.
These discoveries position DDX3X, BCLAF1, and NCL as compelling potential therapeutic targets while spotlighting lactylation pathways as drivers of disease progression. Moving forward, scientists must determine whether directly targeting these genes or broader lactylation pathways yields clinically meaningful antifibrotic effects in patients suffering from progressive pulmonary fibrosis.
Frequently Asked Questions About Lactylation and IPF
What is idiopathic pulmonary fibrosis (IPF)?
Idiopathic pulmonary fibrosis is a chronic, progressive, and irreversible interstitial lung disease characterized by high mortality and progressive scarring of lung tissue.
What are lactylation-related hub genes in IPF?
According to Yue M et al., DDX3X, BCLAF1, and NCL are central lactylation-related genes identified through multiomics analysis that contribute to epithelial changes, fibroblast activation, and immune remodeling in IPF.
Can current drugs target these newly identified pathways?
Molecular docking analyses show favorable predicted binding between proteins from these hub genes and compounds like pirfenidone and curcumin, though clinical effectiveness requires further experimental validation, as reported by Yue M et al.
What are your thoughts on targeting metabolic modifications like lactylation for lung disease? Join the conversation by leaving a comment below, or subscribe to our newsletter for the latest updates in respiratory research.
Worth a look